You just read:

Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

News provided by

Regeneron Pharmaceuticals, Inc.

Jun 06, 2016, 01:00 ET